Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States
Ivasiy R, Madden L, Johnson K, Machavariani E, Ahmad B, Oliveros D, Tan J, Kil N, Altice F. Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States. International Journal Of Drug Policy 2025, 138: 104748. PMID: 40020306, PMCID: PMC12045481, DOI: 10.1016/j.drugpo.2025.104748.Peer-Reviewed Original ResearchConceptsOpioid use disorderSL-BUPXR-BUPUse disorderRetrospective cohort studyExtended-release buprenorphineReduce treatment discontinuationDays of supplyTreatment discontinuationSublingual buprenorphineReduce overdose riskBuprenorphine treatmentCohort studyHigh dosesPrimary outcomeImpact of dosagePatientsBuprenorphineMonthsMg/dayCommercially-insured individualsProportion of individualsOpioidOverdose riskImprove health outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply